Skip to main content
STVN
NYSE Life Sciences

Q3 Revenue Up 8%, Guidance Held, But CEO Warns GLP-1 Slowdown Will Cap 2027 Growth

Tom Rudovsky · Reported by BusinessWire
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$19.74
Mkt Cap
$5.389B
52W Low
$12.89
52W High
$27
52W Position info
53% above low
Off High info
27% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

STVN sits 53% above its 52-week low of $12.89 on elevated volume (2.0× avg).

Summary

Third-quarter revenue rose 8% to €326.1 million, entirely organic, with adjusted EBITDA margin up 150 basis points to 27.2% and adjusted diluted EPS up 14% to €0.16. The Biopharmaceutical and Diagnostic Solutions segment grew 11% organically, offsetting a 12% decline in Engineering. Full-year 2026 guidance is unchanged: revenue of €1.260-1.280 billion, adjusted EBITDA of €335.0-345.2 million, and adjusted diluted EPS of €0.60-0.62. The problem is the outlook. CEO Franco Stevanato said the company now expects lower GLP-1 volumes than previously anticipated, which will temporarily moderate growth in 2027, with only low single-digit growth expected based on what is known today. GLP-1 therapies were roughly 17-18% of third-quarter revenue, so a softer GLP-1 trajectory hits a meaningful slice of the base even as non-GLP-1 biologics grew over 30%. The quarter itself is solid and in line with expectations; the 2027 commentary is what changes the story. Management is on the call at 8:30 a.m. ET today.

At the time of this announcement, STVN was trading at $19.74 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $12.89 to $27.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

STVN - Latest Insights

STVN
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $13.38
Real-time Price: $15.43 info
Change: +$2.05 (+15%) info
Market Cap: $4.212B info
STVN
Nov 04, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $15.43 info
Change: +$1.27 (+9%) info
Market Cap: $4.212B info
STVN
Nov 03, 2026, 4:15 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $14.46
Real-time Price: $15.43 info
Change: +$0.9697 (+7%) info
Market Cap: $4.212B info
STVN
Nov 03, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $14.10
Real-time Price: $15.43 info
Change: +$1.33 (+9%) info
Market Cap: $4.212B info
STVN
Aug 06, 2026, 4:00 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $20.30
Real-time Price: $15.43 info
Change: -$4.87 (-24%) info
Market Cap: $4.212B info